FFreeCE GuideContinuing education · No cost

Academy for Continued Healthcare Learning

Building Clinical Capacity for Optimal Asparaginase-Based Treatment in Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Approaches in Pediatric, Adult, and Adolescent and Young Adult Patients

Asparaginase, a cornerstone of regimens for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in pediatric and adult patients, is frequently complicated by a distinct spectrum of toxicities which pose significant clinical management challenges. The management of ALL/LBL in adolescent and young adults (AYA) is particularly complex, and these patients often have reduced survival due to their unique needs, challenges with transitions of care, and divergent management across different providers and settings.To mitigate barriers and improve outcomes in patients with ALL/LBL, this

Available on demand1 CMEFree course and certificate

Before you enroll

Is this the right course for you?

Building Clinical Capacity for Optimal Asparaginase-Based Treatment in Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Approaches in Pediatric, Adult, and Adolescent and Young Adult Patients is offered by Academy for Continued Healthcare Learning for physicians. Topics in this listing: Clinical practice.

Check the credit type and approval notes below against your credential. The provider handles enrollment, completion and the certificate.

Course details

Provider
Academy for Continued Healthcare Learning
Format
On demand
Profession
Physicians
Credit expiration
Sep 15, 2027
Registration
Free provider account required
Last checked
Oct 10, 2026
Language
English

Credits & eligibility

1 CME

Provider-designated AMA PRA Category 1 Credit. AAPA, AANP and ANCC reciprocity is provider-stated where disclosed; verify acceptance for your credential.

Listed roles: Physician

State scope: No individual state acceptance claim is made in this listing.

ACCME

What’s free

Course access
$0
Assessment
$0
Certificate
$0
Credit reporting
$0 — no separate reporting fee identified

The provider identifies this activity as free continuing education. Complete the stated assessment and claiming requirements.

How to earn your credit

  1. Create an ACHL account, complete the pretest, view the online activity, and score at least 66% on the posttest.
  2. Complete the evaluation. The certificate is immediately available at no fee.

Questions about this course

Is “Building Clinical Capacity for Optimal Asparaginase-Based Treatment in Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Approaches in Pediatric, Adult, and Adolescent and Young Adult Patients” completely free?

The recorded cost is $0 for learning, assessment and the certificate, with no separate reporting fee identified. Academy for Continued Healthcare Learning requires a free account. The provider identifies this activity as free continuing education. Complete the stated assessment and claiming requirements.

Which credit can I earn?

The provider lists 1 CME. Recorded roles: Physician. Match the individual track below to your credential and board before enrolling.

When can I take this course?

This is an on-demand activity in the current collection; follow the source link to begin. The recorded credit expiration date is 2027-09-15.

What do I need to do for the certificate?

Create an ACHL account, complete the pretest, view the online activity, and score at least 66% on the posttest. Complete the evaluation. The certificate is immediately available at no fee. Completion and certificate delivery are handled by Academy for Continued Healthcare Learning; saving this listing does not enroll you or claim credit.

Sources & verification

These are the primary pages supporting this listing. Course recognition and board acceptance should be confirmed for your credential before enrollment.

Your next credential

Free exam preparation for physicians

Preparing for an exam, too? Explore free practice questions and explanations on OpenExamPrep.

OpenExamPrepFree exam preparation
Free practice

USMLE Step 1

200 practice questions Free practice

USMLE Step 2 CK

260 practice questions
Explore all 224 exams for physicians →

These are exam-preparation resources, separate from continuing education credit. Exam registration fees and eligibility are set by the exam sponsor.

Keep exploring

More for your profession
Academy for Continued Healthcare LearningFree
Available on demand

Navigating Complexity in the Post-CDK4/6 Inhibitor Treatment Setting for Patients With ER+/HER2- mBC: Strategies for Optimally Integrating Next-Generation Oral SERDs

The management of hormone receptor–positive (HR-positive), human epidermal growth factor receptor 2–negative (HER2-negative) metastatic breast cancer (mBC) is undergoing rapid transformation, largely driven by the imperative to overcome acquired endocrine resistance, frequently mediated by somatic estrogen receptor 1 (ESR1) mutations. These mutations predict a lack of benefit from further aromatase inhibitor (AI) therapy, making the correct identification and subsequent targeting of these alterations critical for guiding treatment selection. Next-generation oral selective estrogen receptor deg

2 CME + moreOn demand
Checked Oct 10, 2026
Academy for Continued Healthcare LearningFree
Available on demand

Unlocking the Therapeutic Potential of Amylin-Based Therapies for Obesity

Obesity is a chronic, progressive, and relapsing disease that imposes a substantial clinical burden. Despite the availability of approved pharmacologic agents with varying mechanisms of action, efficacy, tolerability, and accessibility, only a small percentage of eligible patients are prescribed evidence-based medications, often due to clinician knowledge gaps, concerns regarding long-term safety, and a persistent but inaccurate perception of obesity as a failure of willpower rather than a multifactorial neuroendocrine disorder. Clinicians also encounter significant limitations with available

1 CMEOn demand
Checked Oct 10, 2026
Academy for Continued Healthcare LearningFree
Available on demand

How Should I Treat AChR-Ab Seronegative gMG? Weighing The Latest Evidence to Inform Precision-Based Care

No two patients with generalized myasthenia gravis (gMG) are the same and individualizing treatment is vital. Clinicians must integrate factors such as age of onset, autoantibody profile, clinical manifestation, gender, and thymic pathology to classify gMG subtypes and tailor treatment strategies. The treatment armamentarium has also recently expanded with novel agents and expanded indications, further complicating decisions.To help clinicians interpret and apply the growing body of evidence in treatment selection across gMG subtypes, this point-counterpoint digital activity uses case-based di

1.5 CMEOn demand
Checked Oct 10, 2026